24. Januar 2022
Cyprumed GmbH enters agreement with Ferring Pharmaceuticals for development or oral drug delivery technology for patient–centric non-invasive peptide therapeutics
Cyprumed GmbH Enters Agreement with Ferring Pharmaceuticals for Development of Oral Drug Delivery Technology for Patient-Centric non-invasive Peptide Therapeutics
Innsbruck, Austria – Cyprumed GmbH announced today that it has entered into a research and early development agreement with Ferring Pharmaceuticals for the development of next generation formulation technology for non-invasive delivery of biologics, with a focus on oral peptide delivery. Peptides and other large molecular therapeutics are usually delivered via injections. From a patient point of view, oral delivery is often the preferred option. A combination of Cyprumed´s proprietary oral formulation know-how with compounds approved for use in pharmaceutical products, providing protection against proteolytic degradation, and shared Ferring-Cyprumed knowledge on drug delivery development has already achieved important steps forward towards a new formulation technology for oral delivery of large macromolecular drugs such as peptides. The agreement will enable Ferring and Cyprumed to collaboratively develop drug delivery solutions that will facilitate the treatment of patients.
„This agreement is a continuation and expansion of previous collaborative research projects between Cyprumed and Ferring. We believe that it will further strengthen ties between Cyprumed and Ferring and is an indicator for the potential of a long-term partnership between our two companies,” said Florian Föger, CEO of Cyprumed GmbH. “Cyprumed is confident that this partnership will contribute to the development of new treatment options for patients. It is exciting for us to announce the continuation of our partnership with Ferring, a company with a strong and unique research & development focus on peptide therapeutics.”
“We are delighted to continue our collaboration with Cyprumed. Our work together over the last years has given rise to promising data and we are continuing to explore opportunities to deliver peptides orally, with the ultimate aim of improving patient care and helping people live better lives,” said Janet Halliday, Associate VP Ferring Controlled Therapeutics & External Technology.
About Cyprumed GmbH
Cyprumed GmbH is a privately held, Austrian based drug delivery company developing innovative proprietary drug delivery technologies with a focus on oral peptide delivery. An advantage of the Cyprumed technology is that it builds upon already approved pharmaceutical excipients. The Cyprumed technology is currently being evaluated in a number of collaborative feasibility studies. Cyprumed was founded in 2015. Initially, Cyprumed received financing funds from STARTUP.TIROL (previously CAST, Center for Academic Spin-offs Tyrol), from the Austrian Wirtschaftsservice GmbH (AWS – the Austrian Government Promotional Bank) and from the Austrian Research Promotion Agency (FFG). For more information on Cyprumed GmbH please visit https://www.cyprumed.net/new/